Medicine and Health Sciences Commons^™

Checkpoint Inhibitor Immune-Related Adverse Events: A Focused Review On Autoantibodies And B Cells As Biomarkers, Advancements And Future Possibilities, John Taylor, Aesha Gandhi, Elin Gray, Pauline Zaenker

Research outputs 2022 to 2026

The use of immune checkpoint inhibitors (ICIs) has evolved rapidly with unprecedented treatment benefits being obtained for cancer patients, including improved patient survival. However, over half of the patients experience immune related adverse events (irAEs) or toxicities, which can be fatal, affect the quality of life of patients and potentially cause treatment interruption or cessation. Complications from these toxicities can also cause long term irreversible organ damage and other chronic health conditions. Toxicities can occur in various organ systems, with common observations in the skin, rheumatologic, gastrointestinal, hepatic, endocrine system and the lungs. These are not only challenging to manage …